BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | May 13, 2020
Regulation

Refusal-to-file letter for BMS-bluebird cell therapy further muddies chances of Celgene payout

Partners BMS and bluebird are insistent that FDA’s refusal-to-file letter for their BCMA-targeting cell therapy is merely the result of a documentation issue that isn’t representative of any larger problem. But the resulting delay, which...
BioCentury | May 12, 2020
Deals

bluebird hopes tough choices today will keep core programs on track

To ensure it can meet its goal of launching four programs by 2022 amid the coronavirus crisis, bluebird has retooled its BCMA CAR T deal with Bristol Myers, opting for $200 million of cash now...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BC Extra | Nov 6, 2019
Clinical News

ASH abstract shows U.S. study confirms efficacy for Legend’s BCMA CAR T

New data from a U.S. trial of anti-BCMA CAR T therapy JNJ-4528 (LCAR-B38M) from J&J and partner Legend Biotech may calm any lingering concerns that data from a previous trial had been manipulated. The data,...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

Biotech watchers are hoping a busy fourth quarter of data readouts, regulatory actions and IPOs will provide some bright spots to counteract the sector’s continued overall underperformance, which is not expected to improve in 2020....
BC Week In Review | Jan 4, 2019
Company News

BMS deal weighs on Celgene partners

The proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) on Jan. 3 put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when...
BC Extra | Jan 4, 2019
Company News

BMS deal weighs on Celgene partners

Thursday’s proposed acquisition of Celgene Corp. (NASDAQ:CELG) by Bristol-Myers Squibb Co. (NYSE:BMY) put pressure on shares of Celgene partners Acceleron Pharma Inc. (NASDAQ:XLRN) and BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) on a day when U.S. stocks across...
BC Week In Review | Dec 7, 2018
Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
BC Extra | Dec 4, 2018
Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
Items per page:
1 - 10 of 19